DENTSPLY SIRONA Inc. (XRAY) — ESG & Values Scores

Environment story

DENTSPLY SIRONA discloses minimal environmental metrics in the 10-K. Scope 1, 2, and 3 emissions are not disclosed; renewable electricity percentage is undisclosed. No net-zero target year is stated. The company faces regulatory compliance costs from evolving climate-disclosure mandates (CSRD, California climate laws, EU AI Act). No significant resource-depletion or toxic-waste controversies are mentioned in the filing. Dental composite products containing BPA are sold, though FDA-approved. The company acknowledges potential climate-related litigation risks and supply-chain climate vulnerabilities (tariff/trade-war impacts, geopolitical disruption) but has not disclosed decarbonization infrastructure investments or offsets. Overall ESG transparency is limited, and greenwashing detection protocols cannot verify emissions reductions or renewable-energy claims.

Criticisms on file

BPA in Dental Composites
Source: XRAY 10-K Risk Factors: 'We manufacture and sell dental filling materials that may contain bisphenol-A (BPA)... public reports and concerns regarding the potential hazards of BPA could contribute to a perceived safety risk.'
Undisclosed Scope 1, 2, 3 Emissions & Net-Zero Target
Source: XRAY 10-K: No mention of absolute emissions, renewable-energy percentage, or net-zero commitment in Risk Factors or MD&A.

Disclosed initiatives

EU CSRD & Climate-Disclosure Compliance

Company acknowledges requirement to comply with EU Corporate Sustainability Reporting Directive and revised European Sustainability Reporting Standards (ESRS) effective 2026, as well as California climate-disclosure laws effective 2026.

Compliance cost; no operational decarbonization stated.
Supply-Chain Risk Management

Company identifies and monitors tariff, trade-war, geopolitical, and climate-related supply-chain disruptions, including potential impacts from extreme weather and natural disasters.

Mitigation planning only; no direct emissions reduction.

Social story

DENTSPLY SIRONA discloses limited workforce and diversity metrics. CEO-to-median-worker pay ratio is not disclosed; diversity percentages for leadership and workforce are absent from the 10-K. Turnover rate is not stated. Union standing is not mentioned. The company acknowledges labor-union and works-council cooperation in context of restructuring (2024 Plan, 2026 Plan), but no active union-suppression or strike activity is documented in this filing. Supply-chain human-rights audits, forced-labor policies, and modern-slavery statements are not mentioned. The company faces potential talent-retention challenges and acknowledges the need for succession planning. No DEI program, supplier-diversity initiatives, or formal pay-equity commitments are disclosed.

Criticisms on file

Undisclosed CEO-to-Median-Worker Pay Ratio
Source: XRAY 10-K: No pay-ratio disclosure in MD&A or Executive Compensation section referenced.
Absent Workforce Diversity Metrics
Source: XRAY 10-K: No breakdown of workforce or leadership diversity by gender, race, or ethnicity provided in filing.
No Documented Supply-Chain Human-Rights Audits
Source: XRAY 10-K: No mention of conflict minerals, forced-labor policies, or modern-slavery statement.

Disclosed initiatives

Workforce Restructuring & Labor Collaboration

2024 and 2026 restructuring plans implemented with coordination involving labor unions and works councils. 2024 Plan streamlined operations; 2026 Plan targets $120M in annualized cost savings.

Potential job losses; union cooperation acknowledged but no commitment to retain headcount or living-wage standards.
Talent Attraction & Retention

Company acknowledges need to attract, engage, develop, and retain employees with necessary skills; emphasis on succession planning for senior leadership.

Strategic priority stated; no quantified outcomes or diversity targets disclosed.

Governance story

DENTSPLY SIRONA has a single-class share structure (no dual-class penalty applies). Board independence percentage is not disclosed in the 10-K. The company does not disclose annual lobbying expenditures; however, Risk Factors acknowledge compliance with FCPA, anti-corruption, trade, and environmental regulations without detailing active lobbying against climate or consumer-protection rules. Material regulatory matters include: (1) completed 2022 internal investigation into financial reporting; SEC investigation closed; securities class-action litigation ongoing; (2) German Tax Investigation (criminal inquiry into 2016–2017 intercompany loans) with no charges filed as of filing date but significant management distraction; (3) voluntary suspension and wind-down of Byte aligner direct-to-consumer business (2% of 2025 revenue, ~5% of assets, impairment charges incurred). Material weakness in internal controls was remediated as of December 31, 2023. No antitrust, consumer-fraud, or privacy-fine proceedings are disclosed. Board governance composition and proxy voting are not detailed in the provided 10-K excerpts.

Criticisms on file

2022 Financial-Reporting Investigation & Securities Class-Action Litigation
Source: XRAY 10-K Risk Factors: 'As a result of the previously reported material weaknesses in internal control over financial reporting which were remediated as of December 31, 2023, which partially arose from the independent investigation regarding certain financial reporting matters conducted by the Audit and Finance Committee... Several securities class action lawsuits were filed against us following our announcement on May 10, 2022... SEC investigation has been closed... we may face additional litigation and regulatory examinations.'
German Tax Criminal Investigation (Intercompany Loans 2016–2017)
Source: XRAY 10-K Risk Factors: 'German tax authorities are currently performing a criminal investigation related to a series of intercompany loans from 2016 and 2017... As of the date of this filing, there have been no charges against the Company or current or former employees... potential outcomes... uncertain.'
Byte Aligner Business Suspension & Impairment
Source: XRAY 10-K Risk Factors: 'On October 24, 2024, we announced the voluntary suspension of the sale and marketing of our direct-to-consumer Byte aligner systems... In January 2025, we announced that Byte aligners would no longer be offered to new patients... assets related to the Byte aligner business are approximately 5% of the Company's assets as of December 31, 2025... charges relating to customer refunds and asset write-offs.'
Undisclosed Board Independence & Lobbying Expenditure
Source: XRAY 10-K: Board independence percentage and annual lobbying spend not disclosed in provided excerpts.

Disclosed initiatives

Internal Controls Remediation

Material weakness in internal control over financial reporting identified in 2022 investigation; remediated as of December 31, 2023. Company continues to implement new global ERP system (2023–ongoing) to standardize processes and enhance financial governance.

Governance improvement post-remediation; ERP implementation remains high-risk and costly.
Compliance & Regulatory Framework

Company maintains policies and procedures for FCPA, anti-corruption, HIPAA, GDPR, CCPA, healthcare-fraud laws, export controls, and cybersecurity regulations.

Compliance infrastructure in place; no evidence of active deregulation lobbying disclosed.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of DENTSPLY SIRONA Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open DENTSPLY SIRONA Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)